IMMUNOBIOLOGY is a prestigious academic journal published by Elsevier GmbH that significantly contributes to the fields of hematology and immunology. With its ISSN 0171-2985 and E-ISSN 1878-3279, this journal has been disseminating impactful research since 1979, positioning itself at the forefront of immunological and hematological advances. The journal holds a commendable ranking of Q2 in Hematology and Q3 in both Immunology and Immunology and Allergy, indicating its relevance and influence within the scientific community, as reflected by its Scopus rankings. Although IMMUNOBIOLOGY operates under a subscription model, it remains dedicated to expanding knowledge across disciplines, fostering innovative research, and facilitating connections among researchers, professionals, and students. Situated in Munich, Germany, this journal is continually evolving and aims to remain an essential resource for the latest discoveries and insights in the realms of immunity and blood disorders, ultimately enhancing our understanding of complex biological systems.

Frontiers in Immunology is a leading open-access journal published by FRONTIERS MEDIA SA since 2010, dedicated to advancing knowledge in the field of immunology. With an impressive Q1 ranking in both Immunology and Allergy as of 2023, this journal exemplifies excellence in research dissemination, positioning itself among the top 22% of relevant literature in the discipline. The journal, based in Switzerland, emphasizes its commitment to open science by ensuring all published research is freely accessible, fostering collaboration and innovation among researchers, professionals, and students alike. With substantial visibility demonstrated by its ranks within the Scopus database—ranked #52 out of 233 in Immunology and Allergy, and #58 out of 236 in Immunology and Microbiology—Frontiers in Immunology serves as a vital platform for cutting-edge research. Researchers are invited to contribute original investigations and reviews that expand the understanding of immune mechanisms, therapeutic advancements, and clinical applications, making it a cornerstone for those looking to push the boundaries of immunological science.

Immunity is a premier journal published by CELL PRESS that has positioned itself at the forefront of immunological research since its inception in 1994. With its ISSN 1074-7613 and E-ISSN 1097-4180, this prestigious journal is recognized for its significant contribution to the fields of Immunology, Allergy, and Infectious Diseases, consistently achieving a Q1 ranking in these categories as per 2023 metrics. The journal is highly esteemed within the academic community, holding impressive Scopus rankings—4th out of 344 in Infectious Diseases and 3rd in both Immunology and Immunology and Allergy—placing it in the 98th percentile. Although not an Open Access journal, it provides critical insights and research developments that empower researchers, healthcare professionals, and students alike. With a commitment to advancing scientific knowledge, Immunity is crucial for those interested in understanding immune responses and their implications for health and disease.

Welcome to the JOURNAL OF IMMUNOLOGY, a prestigious publication associated with the American Association of Immunologists and dedicated to advancing the field of immunology. With a rich history dating back to 1945, this journal is renowned for its high-impact research, evident in its notable 2023 Q1 rankings in both Immunology and Allergy, as well as its strong positions in Scopus rankings—Rank #68 in Immunology and Allergy and Rank #79 in Immunology and Microbiology. Although it operates on a subscription basis, its commitment to publishing cutting-edge studies ensures that it remains a vital resource for scientists, healthcare professionals, and students alike. As the journal continues to pave the way for innovative research and breakthroughs in immunological science, it facilitates a platform for dialogue and discovery among researchers and practitioners across the globe.

CELLULAR SIGNALLING, published by Elsevier Science Inc, is a premier journal within the realm of Cell Biology, boasting an impressive Q2 category ranking as of 2023. With an ISSN of 0898-6568 and an E-ISSN of 1873-3913, the journal has established itself as a critical platform for advancing the understanding of cellular mechanisms and signal transduction pathways since its inception in 1989. Covering a vast array of topics in Biochemistry, Genetics, and Molecular Biology, it ranks notably at 87 out of 285 in the Scopus list, placing it in the 69th percentile among its peers. The journal serves as an invaluable resource for researchers, professionals, and students seeking high-quality, impactful studies that drive forward the field of cellular biology. While it operates under traditional subscription access, its highlights include rigorous peer-reviewed articles, reviews, and insights that continue to shape current scientific discourse.

IMMUNOLOGICAL INVESTIGATIONS, published by Taylor & Francis Inc, is a leading journal in the field of immunology and related medical sciences, with an established presence since 1972. With a focus on cutting-edge research and critical insights in immunological methods and theories, this journal serves as a pivotal platform for researchers, professionals, and students alike. Though it currently holds a Q3 ranking in Immunology and a Q2 ranking in miscellaneous medicine as of 2023, its Scopus rank of #129 out of 236 reflects its dedication to advancing the understanding of immune responses and therapies. The journal's commitment to rigorous peer review and high-quality publications enables it to remain relevant and influential in the ever-evolving landscape of immunological research. Subscription is required to access its extensive archive, which spans critical developments in the field of immunology from 1972 to 2024.

The Journal of Innate Immunity, published by KARGER, stands at the forefront of immunological research, focusing on the critical role of innate immunity in health and disease. With its Open Access model since 2019, the journal ensures broad dissemination of groundbreaking findings and facilitates global scholarly communication. Based in Switzerland and indexed with an impressive Q1 category ranking in Immunology and Allergy for 2023, it occupies a prominent position in the scientific community, ranked #47 out of 233 in the field. Researchers, professionals, and students alike benefit from accessing high-quality, peer-reviewed articles that span from 2008 and will continue to evolve until 2024, reflecting the latest advances and challenges in innate immunity. As an essential resource, it addresses critical questions and shares innovative insights that push the boundaries of our understanding in this dynamic field.

Welcome to the International Journal of Immunopathology and Pharmacology, a premier publication dedicated to advancing the fields of immunology and pharmacology. Published by SAGE Publications Inc., this Open Access journal has been a vital resource since its inception in 1989, providing an expansive platform for innovative research and comprehensive reviews until 2024. With a strong focus on the mechanisms of immune responses and therapeutic developments, our journal stands out with a 2023 impact factor reflected in its Q3 ranking in Immunology and Allergy, and a Q2 ranking in Pharmacology. The journal's Scopus rankings highlight its significance, ranking #174 in Pharmacology, #141 in Medicine, and #156 in Immunology, all affirming its role in contributing to the broader scientific community. Through rigorous peer review and a commitment to high-quality research, the International Journal of Immunopathology and Pharmacology continues to be an essential resource for scientists, healthcare professionals, and students striving to enhance their knowledge and understanding in these critical fields.

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

Central European Journal of Immunology is a premier publication dedicated to advancing the field of immunology and allergy research. Established in 1996 and published by TERMEDIA PUBLISHING HOUSE LTD, this open access journal has consistently provided a platform for innovative research and comprehensive reviews since its transition to open access in 2002. With an ISSN of 1426-3912 and E-ISSN of 1644-4124, it embraces a global readership while being rooted in Poland. The journal, with a notable Q3 ranking in both the categories of immunology and allergy in 2023, positions itself within the competitive landscape of scientific discourse, as reflected in its Scopus rankings. Designed for researchers, professionals, and students, the Central European Journal of Immunology not only disseminates significant findings but also fosters collaboration and innovation in the immunological sciences, making it a vital resource for those seeking to stay current in this rapidly evolving field.